





Focus of research group (I)

Name PI: Michiel Coppens

Department, UMC: Vascular Medicine/Hemophilia

Treatment Centre

Size of research group:


PhD candidates: Bavalia, Hamulyak (thrombosis),

Zwagemaker, Kloosterman, Abdi (bleeding)

Current mission, vision and aims

- 1. Clinical research that can directly impact patient care.
 - a) Management and outcome of anticoagulant associated bleeding
 - b) Management of menorrhagia in women treated with oral anticoagulantion.
 - Oral resorption of DOACs in patients with short bowel syndrome
 - d) Gene therapy for haemophilia A/B
 - e) Bleeding phenotype in non-severe haemophilia











Focus of research group (II)


Current expertise

- Reversal of DOACs / Bleeding registr(ies)
- 2. Mennorhagia (collaboration Middeldorp)
- Oral DOAC resorption in Short Bowel Syndrome (collaboration Mathot/Serlie)
 - Successful pilot, prospective cohort ongoing
- 4. Gene therapy
 - Steering committee AMT-060/Uniqure Phase I/II
- 5. Phenotype in non-severe haem A/B (collaboration Fijnvandraat)
 - Dynamo, Flow cohorts
- 6. National haemophilia collaborations
 - HiN-6, TiN, Opticlot, DAVID, Pride

Current funding

- ZonMW GGG (in afronding)
- CSL Behring Heimburger Grant
- Bayer Haemophilia Awards Program
- Vierde geldstroom











Future plans

Short term (1-2 year) plan Plan:

- Wrap-up ZonMW GGG Grant. Explore international continuation of cohort
- Successful rollout of prospective TPN cohort (expansion to Radboud)
 - Expand to bariatric surgery patients?
- Gene therapy haemophilia
 - PI phase 3 AMT-061/UniQure
 - PI phase I Bayer
- Active participation in current national collaborations

Necessary infrastructure:

- HPLC DOACs (through Mathot)
- Affordable GCP-quality monitoring/support of IIS

Long term (>2 year) plan

Plan:

Try and remain active in two different fields...

Collaboration in ACS Middeldorp